In summary, by a series of in vitro and in vivo studies, we demonstrated that DSF/Cu kills BRAFV600E-mutated thyroid cancer cells and improved their response to BRAF kinase inhibitors through relieving the feedback activation of MAPK/ERK and PI3K/AKT pathways in an ROS-dependent way. The gene discussed is AKT1; the disease is thyroid cancer.